The DOI matches its Crossref record; 323 of the 323 references it cites were found in a registry or an index.
Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease
Abstract
With 27 million cases worldwide documented in 2006, Alzheimer's disease (AD) constitutes an overwhelming health, social, economic, and political problem to nations. Unless a new medicine capable to delay disease progression is found, the number of cases will reach 107 million in 2050. So far, the therapeutic paradigm one‐compound‐one‐target has failed. This could be due to the multiple pathogenic mechanisms involved in AD including amyloid β (Aβ) aggregation to form plaques, τ hyperphosphorylation to disrupt microtubule to form neurofibrillary tangles, calcium imbalance, enhanced oxidative stress, impaired mitochondrial function, apoptotic neuronal death, and deterioration of synaptic transmission, particularly at cholinergic neurons. Approximately 100 compounds are presently been investigated directed to single targets, namely inhibitors of β and γ secretase, vaccines or antibodies that clear Aβ, metal chelators to inhibit Aβ aggregation, blockers of glycogen synthase kinase 3β, enhancers of mitochondrial function, antioxidants, modulators of calcium‐permeable channels such as voltage‐dependent calcium channels,N‐methyl‐D‐aspartate receptors for glutamate, or enhancers of cholinergic neurotransmission such as inhibitors of acetylcholinesterase or butyrylcholinesterase. In view of this complex pathogenic mechanisms, and the successful treatment of chronic diseases such as HIV or cancer, with multiple drugs having complementary mechanisms of action, the concern is growing that AD could better be treated with a single compound targeting two or more of the pathogenic mechanisms leading to neuronal death. This review summarizes the current therapeutic strategies based on the paradigm one‐compound‐various targets to treat AD. A treatment that delays disease onset and/or progression by 5 years could halve the number of people requiring institutionalization and/or dying from AD. © 2011 Wiley Periodicals, Inc. Med Res Rev
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Sussman, J. L., Harel, M., Frolow, F., Oefner, C., Goldman, A., Toker, L., & Silman, I. (1991) · Science · doi:10.1126/science.1678899 · Cited by 2,707
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 2×
“As referred to above, the cholinergic system is the most affected in AD patients with almost 80% of cholinergic neuron loss.(74) Early observations have demonstrated a decrease in ACh concentration within the synaptic cleft.”
BackgroundResultTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
A Century of Alzheimer's Disease
Goedert, M., & Spillantini, M. G. (2006) · Science · doi:10.1126/science.1132814 · Cited by 2,098
Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., & Perry, R. H. (1978) · BMJ · doi:10.1136/bmj.2.6150.1457 · Cited by 2,042
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Oxidative stress in neurodegeneration: Cause or consequence?
Andersen, J. K. (2004) · Nature Medicine · doi:10.1038/nrn1434 · Cited by 1,869
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661
Mattson, M., Cheng, B., Davis, D., Bryant, K., Lieberburg, I., & Rydel, R. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-02-00376.1992 · Cited by 1,627
Regulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561
EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers
Ehrnhoefer, D. E., Bieschke, J., Boeddrich, A., Herbst, M., Masino, L., Lurz, R., Engemann, S., Pastore, A., & Wanker, E. E. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1437 · Cited by 1,434
The multifaceted roles of glycogen synthase kinase 3β in cellular signaling
Grimes, C. A., & Jope, R. S. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00011-9 · Cited by 1,423
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 1×
“Frequently considered as highly selective for CDKs, roscovitine has been shown to interact with several other kinases (DYRK1A, CK1, pyridoxal kinase).(319) Purines are a large family of biologically active molecules, constituting a scaffold of a wide variety of promising drugs, including kinase inhibitors as 2,6,9-tri…”
Background[18] Quantification of β-sheet amyloid fibril structures with thioflavin T
LeVine, H. (1999) · Methods in Enzymology · doi:10.1016/s0076-6879(99)09020-5 · Cited by 1,365
Extending Applicability of the Oxygen Radical Absorbance Capacity (ORAC−Fluorescein) Assay
Dávalos, A., Gómez-Cordovés, C., & Bartolomé, B. (2004) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf0305231 · Cited by 1,207
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C. A., Lee, V. M.-Y., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,196
The GSK3 hypothesis of Alzheimer’s disease
Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191
Translating cell biology into therapeutic advances in Alzheimer's disease
Selkoe, D. J. (1999) · Nature · doi:10.1038/399a023 · Cited by 1,166
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide
Butterfield, D. A., Drake, J., Pocernich, C., & Castegna, A. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02173-6 · Cited by 1,114
Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Inestrosa, N. C., Alvarez, A., Pérez, C. A., Moreno, R. D., Vicente, M., Linker, C., Casanueva, O. I., Soto, C., & Garrido, J. (1996) · Neuron · doi:10.1016/s0896-6273(00)80108-7 · Cited by 1,101
Clinical trial of indomethacin in Alzheimer's disease
Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1609 · Cited by 999
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988
Li, S., Hong, S., Shepardson, N. E., Walsh, D. M., Shankar, G. M., & Selkoe, D. (2009) · Neuron · doi:10.1016/j.neuron.2009.05.012 · Cited by 972
Pharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase.
Harel, M., Schalk, I., Ehret-Sabatier, L., Bouet, F., Goeldner, M., Hirth, C., Axelsen, P. H., Silman, I., & Sussman, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.19.9031 · Cited by 899
Neurobiology of butyrylcholinesterase
Darvesh, S., Hopkins, D. A., & Geula, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1035 · Cited by 891
Parsons, C. G., Danysz, W., & Quack, G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00019-2 · Cited by 878
Alonso, A. D. C., Grundke-Iqbal, I., & Iqbal, K. (1996) · Nature Medicine · doi:10.1038/nm0796-783 · Cited by 859
Oxidative damage in the central nervous system: protection by melatonin
Reiter, R. J. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00052-5 · Cited by 838
Intranasal insulin improves cognition and modulates β-amyloid in early AD
Reger, M. A., Watson, G. S., Green, P. S., Wilkinson, C. W., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Breitner, J. C. S., DeGroodt, W., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000265401.62434.36 · Cited by 830
Principles for the Buffering of Genetic Variation
Hartman IV, J. L. (2001) · Science · doi:10.1126/science.291.5506.1001 · Cited by 808
Principles for the buffering of genetic variation
Hartman, J. L., Garvik, B., & Hartwell, L. (2001) · Science · doi:10.1126/science.1056072 · Cited by 808
Multicomponent therapeutics for networked systems
Keith, C. T., Borisy, A. A., & Stockwell, B. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1609 · Cited by 769
Kryger, G., Silman, I., & Sussman, J. L. (1999) · Structure · doi:10.1016/s0969-2126(99)80040-9 · Cited by 757
Turner, P. R., O’Connor, K., Tate, W. P., & Abraham, W. C. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00089-3 · Cited by 756
Lewis, W. G., Green, L. G., Grynszpan, F., Radić, Z., Carlier, P. R., Taylor, P., Finn, M. G., & Sharpless, K. B. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020315)41:6<1053::aid-anie1053>3.0.co;2-4 · Cited by 744
Greig, N. H., Utsuki, T., Ingram, D. K., Wang, Y., Pepeu, G., Scali, C., Yu, Q.-S., Mamczarz, J., Holloway, H. W., Giordano, T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508575102 · Cited by 734
From magic bullets to designed multiple ligands
Morphy, R., Kay, C., & Rankovic, Z. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03163-0 · Cited by 729
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Kalinowski, D. S., & Richardson, D. R. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.2 · Cited by 721
Treatment of Alzheimer's disease; current status and new perspectives
scarpini, E., Schelterns, P., & Feldman, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00502-7 · Cited by 721
Rezai-Zadeh, K., Shytle, D., Sun, N., Mori, T., Hou, H., Jeanniton, D., Ehrhart, J., Townsend, K., Zeng, J., Morgan, D., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1521-05.2005 · Cited by 713
Druker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707
Parsons, C. G., Stöffler, A., & Danysz, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.013 · Cited by 707
Metals in Alzheimer's and Parkinson's Diseases
Barnham, K. J., & Bush, A. I. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.02.019 · Cited by 695
Multiple roles of HDAC inhibition in neurodegenerative conditions
Chuang, D.-M., Leng, Y., Marinova, Z., Kim, H.-J., & Chiu, C.-T. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.06.002 · Cited by 676
Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37161-7 · Cited by 676
Curtain, C. C., Ali, F., Volitakis, I., Cherny, R. A., Norton, R. S., Beyreuther, K., Barrow, C. J., Masters, C. L., Bush, A. I., & Barnham, K. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100175200 · Cited by 649
Atwood, C. S., Scarpa, R. C., Huang, X., Moir, R. D., Jones, W. D., Fairlie, D. P., Tanzi, R. E., & Bush, A. I. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751219.x · Cited by 641
Alzheimer's Disease: From Pathology to Therapeutic Approaches
Jakob‐Roetne, R., & Jacobsen, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802808 · Cited by 626
Systematic discovery of multicomponent therapeutics
Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620
β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies
Bartolini, M., Bertucci, C., Cavrini, V., & Andrisano, V. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01514-9 · Cited by 568
Cholinesterase inhibitors: new roles and therapeutic alternatives
GIACOBINI, E. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.11.017 · Cited by 555
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Rogers, J. T., Randall, J. D., Cahill, C. M., Eder, P. S., Huang, X., Gunshin, H., Leiter, L., McPhee, J., Sarang, S. S., Utsuki, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207435200 · Cited by 551
A robustness-based approach to systems-oriented drug design
Kitano, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2195 · Cited by 488
Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site
Bourne, Y. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg005 · Cited by 488
ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition
DeMattos, R. B., Cirrito, J. R., Parsadanian, M., May, P. C., O'Dell, M. A., Taylor, J. W., Harmony, J. A. K., Aronow, B. J., Bales, K. R., Paul, S. M., et al. (2004) · Neuron · doi:10.1016/s0896-6273(03)00850-x · Cited by 459
Neuronal and glial calcium signaling in Alzheimer’s disease
Mattson, M. P., & Chan, S. L. (2003) · Cell Calcium · doi:10.1016/s0143-4160(03)00128-3 · Cited by 457
Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process
De Strooper, B. (2010) · Physiological Reviews · doi:10.1152/physrev.00023.2009 · Cited by 455
APP processing is regulated by cytoplasmic phosphorylation
Lee, M.-S., Kao, S.-C., Lemere, C. A., Xia, W., Tseng, H.-C., Zhou, Y., Neve, R., Ahlijanian, M. K., & Tsai, L.-H. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200301115 · Cited by 454
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2959 · Cited by 440
Cellular mechanisms of β-amyloid production and secretion
Sinha, S., & Lieberburg, I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11049 · Cited by 437
In Situ Click Chemistry: Enzyme Inhibitors Made to Their Own Specifications
Manetsch, R., Krasiński, A., Radić, Z., Raushel, J., Taylor, P., Sharpless, K. B., & Kolb, H. C. (2004) · Journal of the American Chemical Society · doi:10.1021/ja046382g · Cited by 423
A Structural Motif of Acetylcholinesterase That Promotes Amyloid β-Peptide Fibril Formation
De Ferrari, G. V., Canales, M. A., Shin, I., Weiner, L. M., Silman, I., & Inestrosa, N. C. (2001) · Biochemistry · doi:10.1021/bi0101392 · Cited by 413
Calcium Signaling and Amyloid Toxicity in Alzheimer Disease
Demuro, A., Parker, I., & Stutzmann, G. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.080895 · Cited by 407
A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402
Calcium Hypothesis of Alzheimer's Disease and Brain Aginga
KHACHATURIAN, Z. S. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb44398.x · Cited by 392
A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease
Scharf, S., Mander, A., Ugoni, A., Vajda, F., & Christophidis, N. (1999) · Neurology · doi:10.1212/wnl.53.1.197 · Cited by 390
Galantamine: A Review of its Use in Alzheimer??s Disease
Scott, L. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200060050-00008 · Cited by 383
Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity.
Takashima, A., Noguchi, K., Sato, K., Hoshino, T., & Imahori, K. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.16.7789 · Cited by 381
Nordberg, A., & Svensson, A.-L. (1998) · Drug Safety · doi:10.2165/00002018-199819060-00004 · Cited by 381
Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders
Youdim, M. B. H., & Buccafusco, J. J. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.11.007 · Cited by 380
Kruman, I., Guo, Q., & Mattson, M. P. (1998) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19980201)51:3<293::aid-jnr3>3.0.co;2-b · Cited by 380
Strategies for optimizing combinations of molecularly targeted anticancer agents
Dancey, J. E., & Chen, H. X. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2089 · Cited by 365
Protection against β‐amyloid peptide toxicity in vivo with long‐term administration of ferulic acid
Yan, J., Cho, J., Kim, H., Kim, K., Jung, J., Huh, S., Suh, H., Kim, Y., & Song, D. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704047 · Cited by 364
Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials
Meijer, L., & Raymond, E. (2003) · ChemInform · doi:10.1002/chin.200336265 · Cited by 362
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
ADAPT Research Group (2007) · Neurology · doi:10.1212/01.wnl.0000260269.93245.d2 · Cited by 354
Metabolic network analysis of the causes and evolution of enzyme dispensability in yeast
Papp, B., Pál, C., & Hurst, L. D. (2004) · Nature · doi:10.1038/nature02636 · Cited by 352
Naturally occurring phytochemicals for the prevention of Alzheimer’s disease
Kim, J., Lee, H. J., & Lee, K. W. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06562.x · Cited by 352
Highly Potent, Selective, and Low Cost Bis-tetrahydroaminacrine Inhibitors of Acetylcholinesterase
Pang, Y.-P., Quiram, P., Jelacic, T., Hong, F., & Brimijoin, S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.39.23646 · Cited by 344
On the participation of higher oxidation states of iron and copper in fenton reactions
Sutton, H. C., & Winterbourn, C. C. (1989) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(89)90160-3 · Cited by 338
Scott, L. E., & Orvig, C. (2009) · Chemical Reviews · doi:10.1021/cr9000176 · Cited by 332
GSK3: a possible link between beta amyloid peptide and tau protein
Hernández, F., Gómez de Barreda, E., Fuster-Matanzo, A., Lucas, J. J., & Avila, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.011 · Cited by 327
Role of Oxidative Stress in the Progression of Alzheimer's Disease
Sultana, R., & Butterfield, D. A. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1222 · Cited by 327
Linking Calcium to Aβ and Alzheimer's Disease
Green, K. N., & LaFerla, F. M. (2008) · Neuron · doi:10.1016/j.neuron.2008.07.013 · Cited by 326
Polinsky, R. J. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80127-6 · Cited by 323
Frantz, S. (2005) · Nature · doi:10.1038/437942a · Cited by 322
Dissection of Amyloid-β Precursor Protein-dependent Transcriptional Transactivation
Cao, X., & Südhof, T. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402248200 · Cited by 309
Khatoon, S., Grundke‐Iqbal, I., & Iqbal, K. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09432.x · Cited by 304
A practical view of ‘druggability’
Keller, T. H., Pichota, A., & Yin, Z. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.014 · Cited by 295
Fagan, A. M., Watson, M., Parsadanian, M., Bales, K. R., Paul, S. M., & Holtzman, D. M. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0483 · Cited by 290
Lipoic acid as a novel treatment for Alzheimer's disease and related dementias
Holmquist, L., Stuchbury, G., Berbaum, K., Muscat, S., Young, S., Hager, K., Engel, J., & Münch, G. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.07.001 · Cited by 288
Takashima, A., Honda, T., Yasutake, K., Michel, G., Murayama, O., Murayama, M., Ishiguro, K., & Yamaguchi, H. (1998) · Neuroscience Research · doi:10.1016/s0168-0102(98)00061-3 · Cited by 287
Ribosomal RNA in Alzheimer Disease Is Oxidized by Bound Redox-active Iron
Honda, K., Smith, M. A., Zhu, X., Baus, D., Merrick, W. C., Tartakoff, A. M., Hattier, T., Harris, P. L., Siedlak, S. L., Fujioka, H., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500526200 · Cited by 280
PPARγ Agonists as Therapeutics for the Treatment of Alzheimer's Disease
Landreth, G., Jiang, Q., Mandrekar, S., & Heneka, M. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.003 · Cited by 277
Beal, M. F. (2004) · Journal of Bioenergetics and Biomembranes · doi:10.1023/b:jobb.0000041772.74810.92 · Cited by 277
Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine
Bukanov, N. O., Smith, L. A., Klinger, K. W., Ledbetter, S. R., & Ibraghimov-Beskrovnaya, O. (2006) · Nature · doi:10.1038/nature05348 · Cited by 276
Ye, S., Huang, Y., Müllendorff, K., Dong, L., Giedt, G., Meng, E. C., Cohen, F. E., Kuntz, I. D., Weisgraber, K. H., & Mahley, R. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508693102 · Cited by 275
Drug Development Based on the Metals Hypothesis of Alzheimer's Disease
Bush, A. I. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15208 · Cited by 267
Piazzi, L., Rampa, A., Bisi, A., Gobbi, S., Belluti, F., Cavalli, A., Bartolini, M., Andrisano, V., Valenti, P., & Recanatini, M. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0340602 · Cited by 266
Biochemistry of Altered Brain Proteins in Alzheimer's Disease
Selkoe, D. J. (1989) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.12.030189.002335 · Cited by 265
Dihydropyridine BAY-K-8644 activates chromaffin cell calcium channels
García, A. G., Sala, F., Reig, J. A., Viniegra, S., Frías, J., Fontériz, R., & Gandía, L. (1984) · Nature · doi:10.1038/309069a0 · Cited by 263
Takashima, A., Noguchi, K., Michel, G., Mercken, M., Hoshi, M., Ishiguro, K., & Imahori, K. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(95)12257-5 · Cited by 260
Bolognesi, M. L., Cavalli, A., Valgimigli, L., Bartolini, M., Rosini, M., Andrisano, V., Recanatini, M., & Melchiorre, C. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm701225u · Cited by 260
Rodríguez-Franco, M. I., Fernández-Bachiller, M. I., Pérez, C., Hernández-Ledesma, B., & Bartolomé, B. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050746d · Cited by 248
Chance and necessity in the evolution of minimal metabolic networks
Pál, C., Papp, B., Lercher, M. J., Csermely, P., Oliver, S. G., & Hurst, L. D. (2006) · Nature · doi:10.1038/nature04568 · Cited by 239
Takeda, A., Loveman, E., Clegg, A., Kirby, J., Picot, J., Payne, E., & Green, C. (2006) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1402 · Cited by 227
Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease
Tiraboschi, P., Hansen, L. A., Masliah, E., Alford, M., Thal, L. J., & Corey-Bloom, J. (2004) · Neurology · doi:10.1212/01.wnl.0000128091.92139.0f · Cited by 226
Rational Approach To Discover Multipotent Anti-Alzheimer Drugs
Rosini, M., Andrisano, V., Bartolini, M., Bolognesi, M. L., Hrelia, P., Minarini, A., Tarozzi, A., & Melchiorre, C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049112h · Cited by 226
Piazzi, L., Cavalli, A., Colizzi, F., Belluti, F., Bartolini, M., Mancini, F., Recanatini, M., Andrisano, V., & Rampa, A. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.09.100 · Cited by 214
Rodríguez-Rodríguez, C., Sánchez de Groot, N., Rimola, A., Álvarez-Larena, Á., Lloveras, V., Vidal-Gancedo, J., Ventura, S., Vendrell, J., Sodupe, M., & González-Duarte, P. (2009) · Journal of the American Chemical Society · doi:10.1021/ja806062g · Cited by 210
Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors
Castro, A., & Martinez, A. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778792985 · Cited by 207
Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)
Mencher, S. K., & Wang, L. G. (2005) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-5-3 · Cited by 206
Camps, P., Formosa, X., Galdeano, C., Gómez, T., Muñoz-Torrero, D., Scarpellini, M., Viayna, E., Badia, A., Clos, M. V., Camins, A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8001313 · Cited by 205
Small Molecule Modulators of Copper-Induced Aβ Aggregation
Hindo, S. S., Mancino, A. M., Braymer, J. J., Liu, Y., Vivekanandan, S., Ramamoorthy, A., & Lim, M. H. (2009) · Journal of the American Chemical Society · doi:10.1021/ja907045h · Cited by 203
Jiang, D., Men, L., Wang, J., Zhang, Y., Chickenyen, S., Wang, Y., & Zhou, F. (2007) · Biochemistry · doi:10.1021/bi700508n · Cited by 202
KHACHATURIAN, Z. S. (1989) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1989.tb12485.x · Cited by 198
Inhibition of fibril formation in β-amyloid peptide by a novel series of benzofurans
Howlett, D. R., PERRY, A. E., GODFREY, F., SWATTON, J. E., JENNINGS, K. H., Spitzfaden, C. E., Wadsworth, H., Wood, S. J., & Markwell, R. E. (1999) · Biochemical Journal · doi:10.1042/bj3400283 · Cited by 197
Design and synthesis of tacrine–ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates
Fang, L., Kraus, B., Lehmann, J., Heilmann, J., Zhang, Y., & Decker, M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.03.073 · Cited by 190
Rizzo, S., Rivière, C., Piazzi, L., Bisi, A., Gobbi, S., Bartolini, M., Andrisano, V., Morroni, F., Tarozzi, A., Monti, J.-P., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8002747 · Cited by 189
Lange, J. H. M., Coolen, H. K. A. C., van Stuivenberg, H. H., Dijksman, J. A. R., Herremans, A. H. J., Ronken, E., Keizer, H. G., Tipker, K., McCreary, A. C., Veerman, W., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031019q · Cited by 189
Effects of Grape Seed-derived Polyphenols on Amyloid β-Protein Self-assembly and Cytotoxicity*
Ono, K., Condron, M. M., Ho, L., Wang, J., Zhao, W., Pasinetti, G. M., & Teplow, D. B. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806154200 · Cited by 188
Rosini, M., Simoni, E., Bartolini, M., Cavalli, A., Ceccarini, L., Pascu, N., McClymont, D. W., Tarozzi, A., Bolognesi, M. L., Minarini, A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800577j · Cited by 185
Lange, J. H. M., van Stuivenberg, H. H., Coolen, H. K. A. C., Adolfs, T. J. P., McCreary, A. C., Keizer, H. G., Wals, H. C., Veerman, W., Borst, A. J. M., de Looff, W., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040843r · Cited by 181
Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans.
Howlett, D. R., Perry, A. E., GODFREY, F., et al. (1999) · PubMed · Cited by 180
Natural Antioxidants Protect Neurons in Alzheimer’s Disease and Parkinson’s Disease
Zhao, B. (2009) · Neurochemical Research · doi:10.1007/s11064-008-9900-9 · Cited by 180
A Small Molecule Targeting the Multifactorial Nature of Alzheimer's Disease
Cavalli, A., Bolognesi, M. L., Capsoni, S., Andrisano, V., Bartolini, M., Margotti, E., Cattaneo, A., Recanatini, M., & Melchiorre, C. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700256 · Cited by 179
Ferreira, A., Lu, Q., Orecchio, L., & Kosik, K. S. (1997) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1997.0615 · Cited by 178
Dysregulation of Cellular Calcium Homeostasis in Alzheimer's Disease: Bad Genes and Bad Habits
Mattson, M. P., & Chan, S. L. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:205 · Cited by 177
Rediscovering the sweet spot in drug discovery
Brown, D., & Superti-Furga, G. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02902-7 · Cited by 176
Central nicotinic receptors, neurotrophic factors and neuroprotection
Belluardo, N., Mudò, G., Blum, M., & Fuxe, K. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00197-2 · Cited by 176
Regulation of Alzheimer's disease amyloid-β formation by casein kinase I
Flajolet, M., He, G., Heiman, M., Lin, A., Nairn, A. C., & Greengard, P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611236104 · Cited by 174
Mandel, S. A., Amit, T., Kalfon, L., Reznichenko, L., Weinreb, O., & Youdim, M. B. H. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15207 · Cited by 173
Current approaches in the treatment of Alzheimer's disease
Shah, R. S., Lee, H.-G., Xiongwei, Z., Perry, G., Smith, M. A., & Castellani, R. J. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.02.005 · Cited by 172
Donepezil for mild cognitive impairment
Birks, J., & Flicker, L. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006104 · Cited by 169
Calcium signalling and Alzheimer's disease
Berridge, M. J. (2011) · Neurochemical Research · doi:10.1007/s11064-010-0371-4 · Cited by 167
ER Calcium and Alzheimer’s Disease: In a State of Flux
Mattson, M. P. (2010) · Science Signaling · doi:10.1126/scisignal.3114pe10 · Cited by 162
Radić, Z., Reiner, E., & Taylor, P. (1991) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10932-2 · Cited by 160
Trombino, S., Serini, S., Di Nicuolo, F., Celleno, L., Andò, S., Picci, N., Calviello, G., & Palozza, P. (2004) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf0303924 · Cited by 159
Fernández‐Bachiller, M. I., Pérez, C., Campillo, N. E., Páez, J. A., González‐Muñoz, G. C., Usán, P., García‐Palomero, E., López, M. G., Villarroya, M., García, A. G., et al. (2009) · ChemMedChem · doi:10.1002/cmdc.200800414 · Cited by 159
Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain
. Swatton, J. E., Sellers, L. A., Faull, R. L. M., Holland, A., Iritani, S., & Bahn, S. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03365.x · Cited by 159
Hikida, T., Kitabatake, Y., Pastan, I. H., & Nakanishi, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0631749100 · Cited by 158
Jönsson, S., Andersson, G. K. A., Fex, T., Fristedt, T., Hedlund, G., Jansson, K., Abramo, L., Fritzson, I., Pekarski, O., Runström, A., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031044w · Cited by 157
Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression
Stahl, S. M., Entsuah, R., & Rudolph, R. L. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01425-7 · Cited by 151
A Pro-Chelator Triggered by Hydrogen Peroxide Inhibits Iron-Promoted Hydroxyl Radical Formation
Charkoudian, L. K., Pham, D. M., & Franz, K. J. (2006) · Journal of the American Chemical Society · doi:10.1021/ja064806w · Cited by 150
Savini, L., Gaeta, A., Fattorusso, C., Catalanotti, B., Campiani, G., Chiasserini, L., Pellerano, C., Novellino, E., McKissic, D., & Saxena, A. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0255668 · Cited by 148
Drug development for Alzheimer's disease: where are we now and where are we headed?
Sabbagh, M. N. (2009) · The American journal of geriatric pharmacotherapy · doi:10.1016/j.amjopharm.2009.06.003 · Cited by 147
Bieschke, J., Zhang, Q., Powers, E. T., Lerner, R. A., & Kelly, J. W. (2005) · Biochemistry · doi:10.1021/bi0501030 · Cited by 145
Jang, S.-W., Liu, X., Chan, C.-B., Weinshenker, D., Hall, R. A., Xiao, G., & Ye, K. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.05.010 · Cited by 144
Rauser, L., Savage, J. E., Meltzer, H. Y., & Roth, B. L. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29304-6 · Cited by 144
Newberg, A. B., Wintering, N., Plößl, K., Hochold, J., Stabin, M. G., Watson, M., Skovronsky, D., Clark, C. M., Kung, M., & Kung, H. F. (2006) · PubMed · Cited by 143
Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat
Tang, X. C., Sarno, P. D., Sugaya, K., et al. (1989) · Journal of Neuroscience Research · doi:10.1002/jnr.490240220 · Cited by 142
Zheng, H., Youdim, M. B. H., & Fridkin, M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900504c · Cited by 141
Strategies for the Inhibition of Protein Aggregation in Human Diseases
Bartolini, M., & Andrisano, V. (2010) · ChemBioChem · doi:10.1002/cbic.200900666 · Cited by 140
Roscovitine-Derived, Dual-Specificity Inhibitors of Cyclin-Dependent Kinases and Casein Kinases 1
Oumata, N., Bettayeb, K., Ferandin, Y., Demange, L., Lopez-Giral, A., Goddard, M.-L., Myrianthopoulos, V., Mikros, E., Flajolet, M., Greengard, P., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800109e · Cited by 139
Sadot, E., Gurwitz, D., Barg, J., Behar, L., Ginzburg, I., & Fisher, A. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66020877.x · Cited by 139
Marco, J. L., Leon, R. M., Ríos, C. D. L., Samadi, A., Bartolini, M., Andrisano, V., Huertas, Ó., Barril, X., Luque, F. J., Rodríguez-Franco, M. I., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801292b · Cited by 137
Treatment Options in Alzheimer’s Disease: Maximizing Benefit, Managing Expectations
Farlow, M. R., Miller, M. L., & Pejović, V. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000122962 · Cited by 136
Bolognesi, M. L., Andrisano, V., Bartolini, M., Banzi, R., & Melchiorre, C. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049156q · Cited by 136
Bryson, H. M., & Benfield, P. (1997) · Drugs & Aging · doi:10.2165/00002512-199710030-00007 · Cited by 136
Bivalent β-Carbolines as Potential Multitarget Anti-Alzheimer Agents
Rook, Y. R. N., Schmidtke, K.-U., Gaube, F., Schepmann, D., Wünsch, B., Heilmann, J., Lehmann, J., & Winckler, T. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1000024 · Cited by 135
Alzheimer 100 – highlights in the history of Alzheimer research
Jellinger, K. A. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0578-3 · Cited by 133
Howlett, D. R., George, A. R., OWEN, D. E., Ward, R. V., & Markwell, R. E. (1999) · Biochemical Journal · doi:10.1042/bj3430419 · Cited by 133
Carlier, P. R., Chow, E. S. ‐., Han, Y., Liu, J., Yazal, J. E., & Pang, Y. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990224w · Cited by 129
Cano‐Abad, M. F., Villarroya, M., Garcı́a, A. G., Gabilan, N. H., & López, M. G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102334200 · Cited by 129
Mechanism of Tau-Induced Neurodegeneration in Alzheimer Disease and Related Tauopathies
Alonso, A. D. C., Li, B., Grundke, I., & Iqbal, K. (2008) · Current Alzheimer Research · doi:10.2174/156720508785132307 · Cited by 128
Amit, T., Avramovich‐Tirosh, Y., Youdim, M. B. H., & Mandel, S. (2008) · The FASEB Journal · doi:10.1096/fj.07-8627rev · Cited by 126
Bolognesi, M. L., Cavalli, A., & Melchiorre, C. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.042 · Cited by 126
Beta-Secretase: Structure, Function, and Evolution
Venugopal, C., Demos, C., Rao, K. S. J., Pappolla, M. A., & Sambamurti, K. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708784936626 · Cited by 125
Tau protein I is essential for amyloid β-protein iduced neurotoxicity
Takashima, A. (1993) · Medical Entomology and Zoology · Cited by 125
Howlett, D. R., George, A. R., OWEN, D. E., Ward, R. V., & Markwell, R. E. (1999) · PubMed Central · Cited by 123
Alzheimers Disease-Associated Neurotoxic Mechanisms and Neuroprotective Strategies
Pereira, C., Agostinho, P. M., Moreira, P. I., Cardoso, S. M., & Oliveira, C. R. (2005) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007054546117 · Cited by 122
Marco, J. L., Leon, R. M., Ríos, C. D. L., Guglietta, A., Terencio, J. V., López, M. G., García, A. G., & Villarroya, M. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm061047j · Cited by 118
Disease modifying therapy for AD?1
Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117
Physostigmine restores3H-acetylcholine efflux from Alzheimer brain slices to normal level
Nilsson, L. M., Nordberg, A. K., Hardy, J., Wester, P. O., & Winblad, B. G. (1986) · Journal of Neural Transmission · doi:10.1007/bf01243353 · Cited by 116
Luna‐Medina, R., Cortés‐Canteli, M., Sánchez-Galiano, S., Morales-Garcia, J. A., Martínez, A., Santos, Á., & Pérez‐Castillo, A. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1004-07.2007 · Cited by 116
Moser, P. C., Bergis, O. E., Jegham, S., Lochead, A. W., Duconseille, E., Terranova, J.-P., Caille, D., Berque‐Bestel, I., Lezoualc’h, F., Fischmeister, R., et al. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034249 · Cited by 116
Non-Steroidal Anti-Inflammatory Drugs and Alzheimers Disease: The Epidemiological Evidence
Szekely, C. A., & Zandi, P. P. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012026 · Cited by 116
Apolipoprotein E, Amyloid, and Alzheimer Disease
Bales, K. R., Dodart, J. C., DeMattos, R. B., Holtzman, D. M., & Paul, S. M. (2002) · Molecular Interventions · doi:10.1124/mi.2.6.363 · Cited by 114
Nostocarboline: Isolation and Synthesis of a New Cholinesterase Inhibitor fromNostoc78-12A
Becher, P. G., Beuchat, J., Gademann, K., & Jüttner, F. (2005) · Journal of Natural Products · doi:10.1021/np050312l · Cited by 112
Combating Alzheimer's Disease With Multifunctional Molecules Designed for Metal Passivation
Schugar, H. J., Green, D. E., Bowen, M. L., Scott, L. E., Storr, T., Böhmerle, K., Thomas, F. C., Allen, D. D., Lockman, P. R., Merkel, M., et al. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200603866 · Cited by 112
Maillard, M. C., Hom, R. K., Benson, T. E., Moon, J. B., Mamo, S., Bienkowski, M. J., Tomasselli, A. G., Woods, D. D., Prince, D. B., Paddock, D. J., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061242y · Cited by 112
Camps, P., Cusack, B. M., Mallender, W. D., Achab, R. E., Morral, J., Muñoz‐Torrero, D., & Rosenberry, T. L. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23214-4 · Cited by 109
Arce, M. P., Rodrı́guez-Franco, M. I., González-Muñoz, G. C., Pérez, C., López, B., Villarroya, M., López, M. G., Garcı́a, A. G., & Conde, S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900628z · Cited by 109
Jaradat, M., Wongsud, B., Phornchirasilp, S., Rangwala, S. M., Shams, G. E.-D. A. M., Sutton, M., Romstedt, K. J., Noonan, D. J., & Feller, D. R. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00822-x · Cited by 109
Mary, A., Renko, D. Z., Guillou, C., & Thal, C. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00133-3 · Cited by 108
Dimeric and Hybrid Anti-Alzheimer Drug Candidates
Munoz-Torrero, D., & Camps, P. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706775527974 · Cited by 107
Cited by
Polypharmacology: Challenges and Opportunities in Drug Discovery: Miniperspective
Anighoro, A., Bajorath, J., & Rastelli, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006463 · Cited by 1,131
Guzior, N., Wi.eckowska, A., Panek, D., & Malawska, B. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106122628 · Cited by 323
A Perspective on Multi-target Drugs for Alzheimer’s Disease
Benek, O., Korabecny, J., & Soukup, O. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.008 · Cited by 260
Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179
Rodríguez-Rodríguez, C., Telpoukhovskaia, M., & Orvig, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.008 · Cited by 151
Metadata
- Authors
- León, R., Garcia, A. G., & Marco‐Contelles, J.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2011-07-26
- Volume
- 33
- Issue
- 1
- Pages
- 139-189
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W1940331911
- Cited by
- 440
- References
- 323
- FWCI
- 10.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.